We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cost-Effectiveness of Vaccination of Older Adults with an MF59 ® -Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden.
- Authors
Jacob, Jorge; Biering-Sørensen, Tor; Holger Ehlers, Lars; Edwards, Christina H.; Mohn, Kristin Greve-Isdahl; Nilsson, Anna; Hjelmgren, Jonas; Ma, Wenkang; Sharma, Yuvraj; Ciglia, Emanuele; Mould-Quevedo, Joaquin
- Abstract
Individuals aged 65 years and above are at increased risk of complications and death from influenza compared with any other age group. Enhanced vaccines, as the MF59®-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose quadrivalent influenza vaccine (HD-QIV), provide increased protection for older adults in comparison to the traditional standard-dose quadrivalent influenza vaccines (SD-QIV). This study aimed to assess the cost-effectiveness of aQIV compared to SD-QIV and HD-QIV in Denmark, Norway, and Sweden for adults aged ≥65 years. A static decision tree model was used to evaluate costs and outcomes of different vaccination strategies from healthcare payer and societal perspectives. This model projects that compared to SD-QIV, vaccination with aQIV could prevent a combined total of 18,772 symptomatic influenza infections, 925 hospitalizations, and 161 deaths in one influenza season across the three countries. From a healthcare payer perspective, the incremental costs per quality adjusted life year (QALY) gained with aQIV versus SD-QIV were EUR 10,170/QALY in Denmark, EUR 12,515/QALY in Norway, and EUR 9894/QALY in Sweden. The aQIV was cost saving compared with HD-QIV. This study found that introducing aQIV to the entire population aged ≥65 years may contribute to reducing the disease and economic burden associated with influenza in these countries.
- Subjects
DENMARK; NORWAY; SWEDEN; INFLUENZA vaccines; OLDER people; VACCINATION; COST effectiveness; VACCINES
- Publication
Vaccines, 2023, Vol 11, Issue 4, p753
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines11040753